格雷夫斯病及甲状腺眼病患者听力功能障碍评估:未接受或接受替妥木单抗治疗
该研究通过医疗索赔数据库和临床试验数据,量化格雷夫斯病(GD)、甲状腺眼病(TED)及接受替妥木单抗治疗患者的耳部相关诊断代码/听力不良事件。结果显示GD、TED和替妥木单抗治疗患者的耳部相关代码发生率相似(24%、33%、32%),最常见的双侧感音神经性听力损失分别为7%、11.1%和10.8%。替妥木单抗治疗前后耳部相关代码发生率分别为17.1%和10.1%。临床试验中耳/迷路疾病发生率为8.1%,其中2.1%被认为与 study drug 相关。
要点
- GD、TED和替妥木单抗治疗患者的耳部相关诊断代码发生率相似(24%、33%、32%)。
- 替妥木单抗治疗前17.1%患者有耳部相关代码,治疗后10.1%出现新发耳部相关代码。
- 替妥木单抗临床试验中耳/迷路疾病发生率为8.1%,2.1%被认为与 study drug 相关。
核心结论
- 分析表明,单纯GD/TED患者与接受替妥木单抗治疗后的患者听力索赔患病率相似。
- 未来评估替妥木单抗增量听力风险的研究应使用预先设计的研究来考虑GD/TED患者背景听力功能障碍。
研究设计与样本
- 研究检查了去标识化的耳/迷路相关ICD-10代码(KOMODO)索赔数据,对象为无TED的GD患者以及无/有替妥木单抗治疗的TED患者。
- 在替妥木单抗临床试验中评估了听力不良事件的发生率/严重程度。
- 比较了替妥木单抗TED试验中无/有听力不良事件患者的GO-QOL评分。
主要发现
- 索赔数据库中识别出GD患者469 720例、TED患者38 566例和替妥木单抗治疗患者967例。
- 耳相关代码(包括非听力特异性代码)出现在24%的GD患者、33%的TED患者和32%的替妥木单抗治疗患者中。
- 「双侧感音神经性听力损失」最常见:GD患者7%(32 961/469 720),TED患者11.1%(4279/38 566),替妥木单抗治疗患者10.8%(104/967)。
- 替妥木单抗使用前,17.1%(165例)患者有耳相关代码,治疗后10.1%(98例)出现新发耳相关代码。
- 八项替妥木单抗肿瘤试验显示8.1%(51/633)患者有耳/迷路疾病,其中2.1%(13例)被认为与 study drug 相关;3.8%(24例)有听力障碍/耳鸣相关不良事件,其中1.3%(8例)被认为与 study drug 相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid eye disease (TED) negatively affects quality of life. TED occurs predominantly in Graves' disease (GD). Teprotumumab improves TED but concern for hearing adverse events (AEs) has emerged. Hearing dysfunction is reported in thyroid autoimmune disease but the background prevalence in GD/TED without teprotumumab remains uncertain. OBJECTIVE: This work aimed to quantify ear-related diagnostic codes/hearing AEs in GD, TED, and patients receiving teprotumumab by examining medical claims and clinical trials. METHODS: Deidentified claims for ear/labyrinth-related International Classification of Disorders, Tenth Revision codes (KOMODO) were examined in GD patients without TED, and TED patients without/with teprotumumab treatment. Hearing AE incidence/severity was evaluated in teprotumumab clinical trials. Graves' Ophthalmopathy Quality of Life questionnaire (GO-QOL) scores were compared in teprotumumab TED trial patients without/with hearing AEs. RESULTS: GD (469 720), TED (38 566) and teprotumumab-treated (967) patients were identified in the claims database. Ear-related codes (including those not specific for hearing) occurred in 24% GD, 33% TED, and 32% teprotumumab-treated patients. "Sensorineural hearing loss bilateral" was most frequent: 7% (32 961/469 720) GD, 11.1% (4279/38 566) TED, and 10.8% (104/967) teprotumumab patients. Before teprotumumab use, 17.1% (165) patients had ear-related codes, while 10.1% (98) had new ear-related codes post treatment.Eight teprotumumab oncology trials revealed 8.1% (51/633) had ear/labyrinth disorders with 2.1% (13) considered study-drug-related and 3.8% (24) hearing impairment/tinnitus-related AEs with 1.3% (8) considered study-drug-related. Similar rates occurred in TED trials.GO-QOL improved in teprotumumab-treated patients without/with hearing AEs. Incidence/severity was consistent across patients with chronic and acute TED. CONCLUSION: These analyses indicate similar prevalence of hearing claims in patients with GD/TED alone as following teprotumumab treatment. Future analyses of incremental hearing risk from teprotumumab should use a priori study designs accounting for background hearing dysfunction in patients with GD/TED.
引用
- Smith TJ, Holt RJ, Fu Q, et al. Assessment of Hearing Dysfunction in Patients With Graves' Disease and Thyroid Eye Disease Without or With Teprotumumab. J Clin Endocrinol Metab. 2025. PMID: 39138817. doi:10.1210/clinem/dgae560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。